concept of SeCT therapy is based on a strategy of preferentially tagging specific cells with a biological small molecule. In contrast to traditional chemotherapy that directly eliminates cancer cells using highly cytotoxic drugs, the principal benefit of SeCT therapy allows cancer cells to be tagged using non-toxic chemical moieties that can either disrupt cellular function (ex/ inhibitors of adhesion) or elicit immunological responses (ex/ antigens). Subsequent functional impairment or related Therapeutic in vivo synthetic chemistry by glycosylated artificial metalloenzymeKatsunori TanakaFigure. Therapeutic in vivo synthetic chemistry exemplified by (A)-(C) in vivo drug-tagging therapy (SeCT) and (D) in vivo drug synthesisimaging results, preferential organ labeling could be achieved depending on the identity of the attached glycans; α(2,6)-sialic acid terminated glycans targeted the liver, while Gal terminated glycans targeted the intestines. In the controls, on the other hands, the localization of fluorescence labeling was not exhibited in targeted organs. Given the promising results, more recently, we represented research on selective cell tagging (SeCT) therapy in vivo via the GArM-Au-1 (Figure B)7). The 110
元のページ ../index.html#110